An interventional study of Anatomic lung resection procedure in NSCLC Stage II and NSCLC Stage I, sponsored by Regina Elena Cancer Institute. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Regina Elena Cancer Institute · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy — 156 open to participants now, 287 under way, 105 of them phase 3. Carcinoma, Non-Small-Cell Lung · Italy.
Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, this one is the 590th largest by planned enrollment of the 640 interventional ones that give a count, is one of 56 that started in 2025, is one of 25 with no phase, reaches primary completion later than 96 of the 286 other live ones, and was the 716th registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →156 of the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Italy, United States, Argentina and 10 more countries
Ages 18+
Hoffmann-La Roche · Sites in Italy, United States, Argentina and 16 more countries
Ages 18+
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+ · Healthy volunteers
Bristol-Myers Squibb · Sites in Italy, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
716 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 291 · Phase 3 265 · Phase 4 6
First in 1994; this study’s year is marked. 56 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 251 across the 640 interventional studies, 200 across the 67 observational. Of the 386 that completed or were terminated, 242 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
560 of 716 have an industry lead sponsor. The 10 most frequent:
Regina Elena Cancer Institute is the lead sponsor of 95 studies on the registry; 51 are open to participants now.
Regina Elena Cancer Institute has 4 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
67 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Italy that are under way reach primary completion within a year, 19 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05609968Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | 2027-01-12 |
Add all 67 to your calendar (.ics) → With an account.
Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate potential major intraoperative and postoperative complications associated with the use of the DaVinci SP® robotic system-via either an intercostal or subcostal approach-during anatomical lung resections in thoracic surgery.
Major complications include: intraoperative conversion to a different surgical technique (thoracoscopy, multi-port robotic surgery) or a different access method (thoracotomy, placement of additional trocars); the need for unplanned intraoperative maneuvers not included in the standard surgical procedure; and the development of bronchopleural fistulas within 10 days.
A single-center, randomized, two-arm (1:1) pilot experimental study on a surgical procedure, investigating the use of two different approaches with the Da Vinci SP® robotic system for anatomical lung resections in thoracic surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lateral subcostal incision between the costal margin and the upper abdomen
Procedure: Anatomic lung resection procedure
intercostal access in the 5th-6th anterolateral intercostal space
Procedure: Anatomic lung resection procedure
Anatomic lung resection procedure for NSCLC, to be performed using the Da Vinci SP® robot.
Total percentage of major complications
Evaluate the percentage of total major complications (intraoperative and postoperative). Complications are defined as: intraoperative conversion to a different technique (thoracoscopy, multi-port robotic surgery) or a different surgical approach (thoracotomy, placement of additional trocars); the need for unplanned intraoperative maneuvers not included in the standard procedure; or the occurrence of bronchopleural fistulas.
Time frame: Within 10 days
Docking time
Docking time is defined as the time interval, expressed in minutes, between the skin incision and the first maneuver performed at the console.
Time frame: 100 minutes
Volume of pleural drainage
collection and monitoring of pleural volume, expressed in milliliters.
Time frame: 30 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Oct 2026, 10 months.
Of 344 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's 10 months is below that.
Counting every sponsor, half of 360 studies reached it within 51 months; a quarter within 26 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Regina Elena Cancer Institute